Ceruloplasmin (Cp) and iron in connection with Parkinson's disease (PD) and Alzheimer's disease (AD);Serúlóplasmín og járn. Tengsl vio Alzheimersjúkdóm og Parkinsonsjúkdóm

Laeknabladid

Volumn 98, Issue 10, 2012, Pages 531-537

  Johannesson, T ^a   Kristinsson, J ^a   Torsdottir, G ^b   Snaedal, J ^b  

^a UNIVERSITY OF ICELAND   (Iceland)

^b LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

Aceruloplasminaemia; Alzheimer's disease; Ceruloplasmin; Copper; Iron; Parkinson's disease

Indexed keywords

CERULOPLASMIN; IRON;

ALZHEIMER DISEASE; BLOOD; BRAIN; DEGENERATIVE DISEASE; ENZYMOLOGY; GENETICS; HUMAN; IRON METABOLISM DISORDER; METABOLISM; OXIDATION REDUCTION REACTION; PARKINSON DISEASE; PATHOLOGY; REVIEW;

ALZHEIMER DISEASE; BRAIN; CERULOPLASMIN; HUMANS; IRON; IRON METABOLISM DISORDERS; NEURODEGENERATIVE DISEASES; OXIDATION-REDUCTION; PARKINSON DISEASE;

EID: 84867472755     PISSN: 00237213     EISSN: 16704959     Source Type: Journal    
DOI: 10.17992/lbl.2012.10.457     Document Type: Article

References (49)

1. Jóhannesson P, Kristinsson J, Snædal J. Hrö rnunarsjúkdómar í heila - oxavarnarensím og kopar. Kynning á rannsóknum. Læknablaoio 2003;89:659-71.
2. Torsdottir G, Kristinsson J, Sveinbjörnsdottir S, Snaedal J, Johannesson T. Copper, ceruloplasmin, superoxide dismutase and iron parameters in Parkinson's disease. Pharmacol Toxicol 1999;85:239-43.
3. Torsdottir G, Sveinbjörnsdottir S, Kristinsson J, Snaedal J, Johannesson T. Ceruloplasmin and superoxide dismutase (SOD1) in Parkinson's disease: A follow-up study. J Neurol Sci 2006;241:53-8.
4. Snaedal J, Kristinsson J, Gunnarsdottir S, Olafsdottir A, Baldvinsson M, Johannesson T. Copper, ceruloplasmin and superoxide dismutase in patients with Alzheimer's disease. A case-control study. Dement Geriatr Cogn Disord 1998;9:239-42. (Cp-sérvirkni í pessari rannsókn, sem nefnd er í meginmáli, var fyrst reiknuo út síoar.)
5. Torsdottir G, Kristinsson J, Snaedal J, Johannesson T. Ceruloplasmin and iron proteins in the serum of patients with Alzheimer's disease. Dement Geriatr Cogn Disord Extra 2011;1:366-71.
6. Holmberg CG, Laurell CB. Investigations in serum copper I. Nature of serum copper and its relation to the ironbinding protein in human serum. Acta Chem Scand 1947;1:944-50.
7. Harris ZL, Morita H, Gitlin JD. The biology of human ceruloplasmin. In: Messerschmidt A, ed. Multi-Copper Oxidases (chapter 10). World Scientific, Singapore 1997:285-305.
8. Harris ZL, Takahashi Y, Miyajima H, Serizawa M, MacGillivray RTA, Gitlin JD. Aceruloplasminemia: Molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci 1995;22:2539-43.
9. Vassiliev V, Harris ZL, Zatta P. Ceruloplasmin in neurodegenerative diseases. Brain Res Rev 2005;49:633-40.
10. Texel SJ, Xu X, Harris ZL. Ceruloplasmin in neurodegenerative diseases. Biochem Soc Trans 2008;36:1277-81.
11. Barber EF, Cousins RJ. Interleukin-1-stimulated induction of ceruloplasmin synthesis in normal and copper-deficient rats. J Nutr 1988;118:375-81.
12. Barber EF, Cousins RJ. Induction of ceruloplasmin synthesis by retinoic acid in rats: Influence of dietary copper and vitamin A status. J Nutr 1987;117:1615-22.
13. Roberts EA, Sarkar B. Liver as a key organ in the supply, storage, and excretion of copper. Am J Clin Nutr 2008;88(suppl):851S-854S.
14. Torsdottir G, Gudmundsson G, Kristinsson J, Snaedal J, Johannesson T. Ceruloplasmin and superoxide dismutase (SOD1) in heterozygotes for Wilson disease: A case control study. Neuropsychiatr Dis Treat 2009;5:55-9.
15. Patel BN, David S. A novel glycosylphosphatidylinositolanchored form of ceruloplasmin is expressed by mammalian astrocytes. J Biol Chem 1997;272:20185-90.
16. Hellman NE, Gitlin JD. Ceruloplasmin metabolism and function. Ann Rev Nutr 2002;22:439-58.
17. Harris ZL, Klomp LW, Gitlin JD. Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis. Am J Clin Nutr 1998;67(Suppl):972S-977S.
18. Harris ZL, Durley AP, Man TK, Gitlin JD. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. Proc Natl Acad Sci 1999;96:10812-7.
19. Jeong SY, David S. Glycosylphosphatidylinositolanchored ceruloplasmin is required for iron efflux from cells in the central nervous system. J Biol Chem 2003;278:27144-8.
20. De Domenico I, Ward DM, di Patti MCB, Jeong SY, David S, Musci G, Kaplan J. Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmin. EMBO J 2007;26:2823-31.
21. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 2004;5:863-73.
22. Altamura S, Muckenthaler MU. Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. J Alzheimer's Dis 2009;16:879-95.
23. Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 2004;3:205-14.
24. Arnal N, Cristalli DO, de Alaniz MJT, Marra CA. Clinical utility of copper, ceruloplasmin, and metallothionein plasma determinations in human neurodegenerative patients and their first-degree relatives. Brain Res 2010;1319:118-30.
25. Bharucha KJ, Friedman JK, Vincent AS, Ross ED. Lower serum ceruloplasmin levels correlate with younger age of onset in Parkinson's disease. J Neurol 2008;255:1957-62.
26. Jin L, Wang J, Zhao L, Jin H, Fei G, Zhang Y, et al. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease. Brain 2011;134:50-8.
27. Martinez-Hernandez R, Montes S, Higuera-Calleja J, Yescas P, Boll MC, Diaz-Ruiz A, et al. Plasma ceruloplasmin ferroxidase activity correlates with the nigral sonographic area in Parkinson's disease patients: A pilot study. Neurochem Res 2011;36:2111-5.
28. Berg D, Hochstrasser H, Schweitzer KJ, Riess O. Disturbance of iron metabolism in Parkinson's disease - ultrasonography as a biomarker. Neurotox Res 2006;9:1-13.
29. Hochstrasser H, Bauer P, Walter U, Behnke S, Spiegel J, Csoti I, et al. Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease. Neurology 2004;63:1912-7.
30. Zecca L, Casella L, Albertini A, Bellei C, Zucca FA, Engelen M, et al. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease. J Neurochem 2008;106:1866-75.
31. Uversky VN. Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res 2004;318:225-41.
32. Inden M, Kitamura Y, Abe M, Tamaki A, Takata K, Taniguchi T. Parkinsonian rotenone mouse model: Reevaluation of long-term administration of rotenone in C57BL/6 mice. Biol Pharm Bull 2011;34:92-6.
33. Hineno A, Kaneko K, Yoshida K, Ikeda S. Ceruloplasmin protects against rotenone-induced oxidative stress and neurotoxicity. Neurochem Res 2011;36:2127-35.
34. Blennow K. Alzheimers sykdom - patofysiologi. Information från Läkemedelsverket 2002;7/8:21-34.
35. Connor JR, Menzies SL, St Martin SM, Mufson EJ. A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. J Neurosci Res 1992;31:75-83.
36. Connor JR, Snyder BS, Beard JL, Fine RE, Mufson EJ. Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease. J Neurosci Res 1992;31:327-35.
37. Smith MA, Harris PLK, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redoxgenerated free radicals. Proc Natl Acad Sci 1997;94:9866-8.
38. Smith MA, Zhu X, Tabaton M, Liu G, McKeel DW, Cohen ML, et al. Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J Alzheimers Dis 2010;19:363-72.
39. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001;60:759-67.
40. Torsdottir G, Kristinsson J, Snaedal J, Sveinbjörnsdottir S, Gudmundsson G, Hreidarsson S, et al. Case-control studies on ceruloplasmin and superoxide dismutase (SOD1) in neurodegenerative diseases: A short review. J Neurol Sci 2010;299:51-4.
41. Brewer GJ, Kanzer SH, Zimmerman EA, Celmins DF, Heckman SM, Dick R. Copper and ceruloplasmin abnormalities in Alzheimer's disease. Am J Alzheimers Dis Other Demen 2010;25:490-7.
42. Bucossi S, Ventriglia M, Panetta V, Salustri C, Pasqualetti P, Mariani S, et al. Copper in Alzheimer's disease: A metaanalysis of serum, plasma, and cerebrospinal fluid studies. J Alzheimers Dis 2011;24:175-85.
43. Squitti R, Ghidoni R, Scrascia F, Benussi L, Panetta V, Pasqualetti P, et al. Free copper distinguishes mild cognitive impairment subjects from healthy elderly individuals. J Alzheimers Dis 2011;23:239-48.
44. Schrag M, Mueller C, Oyoyo U, Smith MA, Kirsch WM. Iron, zinc and copper in the Alzheimer's disease brain: A quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion. Prog Neurobiol 2011;94:296-306.
45. Choi BS, Zheng W. Copper transport to the brain by the blood-brain barrier and blood-CSF barrier. Brain Res 2009;1248:14-21.
46. Logroscino G, Marder K, Graziano J, Freyer G, Slavkovich V, Lo Iacono N, et al. Altered systemic iron metabolism in Parkinson's disease. Neurology 1997;49:714-7.
47. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011;43:429-36.
48. Sveinbjörnsdottir S, Hicks AA, Jonsson T, Petursson H, Gudmundsson G, Frigge, et al. Familial aggregation of Parkinson's disease in Iceland. N Engl J Med 2000;343:1765-70.
49. Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008;321:1218-21.